Cargando…

Nuclear AURKA acquires kinase-independent transactivating function to enhance breast cancer stem cell phenotype

Centrosome-localized mitotic Aurora kinase A (AURKA) facilitates G2/M events. Here we show that AURKA translocates to the nucleus and causes distinct oncogenic properties in malignant cells by enhancing breast cancer stem cell (BCSC) phenotype. Unexpectedly, this function is independent of its kinas...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Feimeng, Yue, Caifeng, Li, Guohui, He, Bin, Cheng, Wei, Wang, Xi, Yan, Min, Long, Zijie, Qiu, Wanshou, Yuan, Zhongyu, Xu, Jie, Liu, Bing, Shi, Qian, Lam, Eric W.-F., Hung, Mien-Chie, Liu, Quentin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4735655/
https://www.ncbi.nlm.nih.gov/pubmed/26782714
http://dx.doi.org/10.1038/ncomms10180
Descripción
Sumario:Centrosome-localized mitotic Aurora kinase A (AURKA) facilitates G2/M events. Here we show that AURKA translocates to the nucleus and causes distinct oncogenic properties in malignant cells by enhancing breast cancer stem cell (BCSC) phenotype. Unexpectedly, this function is independent of its kinase activity. Instead, AURKA preferentially interacts with heterogeneous nuclear ribonucleoprotein K (hnRNP K) in the nucleus and acts as a transcription factor in a complex that induces a shift in MYC promoter usage and activates the MYC promoter. Blocking AURKA nuclear localization inhibits this newly discovered transactivating function of AURKA, sensitizing resistant BCSC to kinase inhibition. These findings identify a previously unknown oncogenic property of the spatially deregulated AURKA in tumorigenesis and provide a potential therapeutic opportunity to overcome kinase inhibitor resistance.